BCG vaccine nesting birds and rusted electrical conduits. The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines. On October 29, 2014 Health Canada gave the permission for Sanofi to resume production of BCG. The global supply situation was analyzed in 2017 and concluded that the global supply is sufficient to meet forecasted BCG vaccine demand but risks for shortages remain mainly due to supply concentration. A weakened strain of bovine tuberculosis bacillus, "Mycobacterium bovis" is specially subcultured in a culture medium, usually Middlebrook 7H9. Some BCG vaccines are freeze dried and become
BCG vaccine Numerous medical studies on treatment of these abscesses with antibiotics have been done with varying results, but the consensus is once pus is aspirated and analysed, provided no unusual bacilli are present, the abscess will generally heal on its own in a matter of weeks. The characteristic raised scar BCG immunization leaves is often used as proof of prior immunization. This scar must be distinguished from that of smallpox vaccination, which it may resemble. BCG immunization generally causes some pain and scarring at the site of injection. The main adverse effects are keloids—large, raised scars. The insertion of deltoid is